ATORGAMA table. 20 mg. 28 tablets

ATORGAMA table. 20 mg. 28 tablets
€ 15.00
Add to Cart
Atorgamma be used in addition to a change in diet, ss to reduce elevated total cholesterol, cholesterol LDL, apolipoprotein B and triglycerides in patients with primary hypercholesterolaemia, heterozygous familial hypercholesterolemia or combined hyperlipidemia

ATORGAMA table. 20 mg. 28 tablets


Atorgamma be used in addition to a change in diet, ss to reduce elevated total cholesterol, cholesterol LDL, apolipoprotein B and triglycerides in patients with primary hypercholesterolaemia, heterozygous familial hypercholesterolemia or combined hyperlipidemia, if not achieved satisfactory results after held a special diet or other medications.
Atorgamma be used in combination therapy, for example with other reducing LDL cholesterol drugs, or if they did not achieve satisfactory results after another led to treatment to reduce total cholesterol and LDL cholesterol in patients with homozygous familial hypercholesterolemia.


Patients should undergo a standard diet holesterolponizhavashta before being prescribed Atorgamma, it is necessary to continue the diet and during treatment with Atorgamma. Dosage should be individualized, depending on baseline cholesterol LDL, the goal of therapy and response.
The usual starting dose is 10 mg once daily. Dosage adjustments should be made at intervals of 4 weeks or more. The maximum dose is 80 mg once daily. Doses should be taken at any time during the day with or without food.
Primary hypercholesterolaemia and combined hyperlipidaemia
The appropriate dose for most patients is 10 mg. Proven is a response within 2 weeks, and maximum response is usually achieved within 4 weeks. The answer remains in treatment.
Heterozygous familial hypercholesterolemia
The starting dose is 10 mg per day. Dosage should be individualized for each patient and adjusted at intervals of 4 weeks to 40 mg daily. The dose of atorvastatin may be increased or 80 mg daily or 40 mg daily, but in combination with a bile acid chelating agents.
Homozygous familial hypercholesterolemia
In a study of 64 patients, including 46 with homozygous familial hypercholesterolemia, atorvastatin was administered at doses up to 80 mg. For these 46 patients the mean reduction in LDL cholesterol was 21%
Patients with homozygous familial hypercholesterolemia received atorvastatin at doses of 10-80 mg daily, in addition to other lipid-lowering therapy in the blood, in cases where no satisfactory results have been achieved by other treatment.
Patients with impaired renal function
Kidney disease does not affect either the plasma or the effect of atorvastatin on blood lipids and therefore does not require dose adjustment.
The efficacy and safety when used in recommended doses for patients over 70 years are similar as for other adults.
Children and adolescents
Use in children should be carried out under the supervision of a specialist.
Experience in the use of this medicine in children is limited and restricted to a small group of patients with severe hyperlipidemia abnormal as homozygous familial hypercholesterolemia. The recommended starting dose for these patients is 10 mg atorvastatin daily. Based on the response and tolerance, the dose may be increased to 80 mg daily. There analyzed data on the safety and effects on the development of this group of patients using atorvastatin.


Atorgamma is contraindicated in:
 Patients with a history of hypersensitivity to the active substance or to any of the excipients
 Patients with active liver disease or unexplained elevated serum transaminases
 Patients with myopathy
 Pregnancy and lactation
 Women of childbearing age who do not use contraceptives
Pregnancy and lactation
Atorgamma is contraindicated during pregnancy and lactation. Women of childbearing age should use effective contraception during treatment.
The safety profile of atorvastatin when used during pregnancy and lactation has not been established.


Atorvastatin is not known to affect ability to drive and use machines.
The most common adverse reactions that can be expected are symptoms of gastrointestinal system, including constipation, flatulence, dyspepsia, and abdominal pain that resolved with continued treatment. Less than 2% of patients were excluded from klinichini trials due to adverse events associated with atorvastatin
Blood and lymphatic system disorders:
Uncommon - thrombocytopenia
Nervous system disorders:
Common - headache, dizziness, paraesthesia, hypoaesthesia
Uncommon - peripheral neuropathy
Ear and labyrinth disorders:
Uncommon - tinnitus
Gastrointestinal disorders:
Common - constipation, flatulence, dyspepsia, nausea, diarrhea
Uncommon - anorexia, vomiting
Skin and subcutaneous tissue disorders:
Common - rash, itching
Uncommon - Urticaria
Very rare - angioedema, bullous eruptions
Musculo-skeletal and connective tissue disorders:
Common - mialgaya, arthralgia
Uncommon - myopathy
Rare - myositis, rhabdomyolysis
Endocrine disorders:
Uncommon - alopitsiya, hyper-or hipoglikeziya, pancreatitis
General disorders and administration site conditions:
Common - fatigue, chest pain, back pain, peripheral edema
Uncommon - malaise, weight display
Immune system disorders:
Common - hypersensitivity
Very rare - anaphylaxis
Hepatobiliary disorders:
Rare - hepatitis, cholestatic jaundice
Reproductive system and breast disorders:
Uncommon - Impotence
Psychiatric disorders:
Common - insomnia
Uncommon - amnesia


mannitol, microcrystalline cellulose, calcium carbonate, povidone, croscarmellose sodium, sodium lauryl sulfate, silica colloidal anhydrous, magnesium stearate.
Tablet coating:
hypromellose 6 cP, titanium dioxide
€ 15.00
Add to Cart